جست‌وجوی استاد و پژوهشگر

Nunzio Cardulloمشاهده پروفایل

پژوهشگر

• Organic Chemistry
• Natural Product Chemistry
• Pharmaceutical Chemistry
• +۵ مورد دیگر

Nunzio Cardullo is a Temporary Researcher (RTD-B) in Organic Chemistry (SSD CHIM/06) at the Department of Chemical Sciences, University of Catania , where he has held positions since 2022. His research focuses on bioactive natural polyphenols and their derivatives, emphasizing chemo-enzymatic synthesis , hybrid molecule design , and ophthalmic drug delivery systems . He also investigates bioactive compounds from Mediterranean plants and enzyme inhibition kinetics for metabolic disorders. Bachelor's (2009) and Master's (2012) in Chemistry from University of Catania PhD in Chemical Sciences (2016) with research on anticancer polyphenols Erasmus+ training (2015) at University of Helsinki His scholarly output spans drug discovery (e.g., Tankyrase inhibitors, BCRP antagonists), nanoformulations (SLNs for neuroblastoma and colorectal cancer), and green chemistry (extraction from agricultural waste, microwave-assisted processes). Key collaborations include Prof. V. Muccilli and Prof. C. Tringali. Awards include Erasmus+ Scholarship and National Scientific Qualification for associate professor . Current projects involve LabCoNaBi at University of Catania.

Paul Wenderمشاهده پروفایل

استاد

• Drug Delivery
• Medicinal Chemistry
• Organometallic Chemistry
• +۹ مورد دیگر

Dr. Paul Wender is the Francis W. Bergstrom Professor of Chemistry at Stanford University, with a courtesy appointment in the Department of Chemical and Systems Biology. He received his B.S. from Wilkes University and Ph.D. in Chemistry from Yale University, followed by an NIH Postdoctoral Fellowship at Columbia University. He served on the faculty at Harvard before joining Stanford. Affiliations : Bio-X, Sarafan ChEM-H, Stanford Cancer Institute His research spans chemistry, biology, and medicine, focusing on drug delivery, molecular imaging, and synthesis. Key projects include eradication of HIV/AIDS, overcoming resistant cancers, and treating neurodegenerative disorders like Alzheimer's disease. His group develops novel computational tools, reactions, and transporters (e.g., CARTs) for therapeutic applications. Recent publications highlight advancements in RNA delivery (2024-2025) using guanidinylated serinol and isoprenoid CARTs, PKC modulator studies for HIV latency reversal, and vancomycin conjugates to combat antibiotic resistance. These works demonstrate his interdisciplinary approach bridging chemistry and biomedical challenges. Scientific Awards : Royal Society of Chemistry’s Sir Derek Barton Gold Medal (2024) Tetrahedron Prize for Creativity in Organic Chemistry (2012) Arthur C. Cope Award (2015) Prelog Medal (2013) Ernest Guenther Award (1988) As an educator, he has received multiple teaching honors, including the Hoagland Prize and Dean’s Teaching Award. His lab sponsors postdoctoral researchers and doctoral candidates, with collaborations across Stanford’s Medical School and external institutions.

• Pharmaceutical Sciences
• Analytical Chemistry
• Drug Pharmacokinetics
• +۵ مورد دیگر

Ahmed Ali is an Assistant Professor at the School of Pharmacy, Notre Dame of Maryland University (NDMU). His research focuses on pharmaceutical analysis, lipidomics, and bioanalytical method development for clinical research. He works in collaboration with institutions including the University of Maryland and Technical University Braunschweig. Ph.D. in Pharmaceutical Analytical Chemistry, Minia University (2013) Postdoctoral training at University of Maryland (SARS-CoV-2 lipid detection), Pacific University Oregon (hypertension research), and Technical University Braunschweig (drug binding affinity studies) Research Interests Drug Pharmacokinetics: Development of separation techniques (CE, HPLC, UPLC, HPTLC) for pharmaceutical and biological analysis Lipidomics & Metabolomics: Mass spectrometry platforms for biomarker discovery and disease mechanism research Bioanalysis: Solid-phase extraction and chromatographic methods for clinical research applications Oligonucleotide Analysis: Advanced chromatography and mass spectrometry for synthetic oligonucleotides Recent Publications highlight his work in antiviral drug analysis (molnupiravir, favipiravir), therapeutic drug monitoring (glibenclamide, metformin), and lipid characterization during SARS-CoV-2 infection using LC-MS techniques. Professional Affiliations: American Association of Colleges of Pharmacy (AACP) Royal Society of Chemistry (RSC) American Society of Mass Spectrometry (ASMS) American Association of Pharmaceutical Scientists (AAPS)

Ned B. Bowdenمشاهده پروفایل

استاد

• Organic Chemistry
• Polymer Science
• Materials Science
• +۵ مورد دیگر

Professor Ned B. Bowden is a faculty member in the Department of Chemistry at the University of Iowa . His interdisciplinary research bridges organic chemistry, polymer science, and materials engineering with applications in membrane technology, agricultural productivity, and biomedical innovations . He holds a BS from Caltech, a PhD from Harvard University, and completed postdoctoral research at Stanford University. Current Affiliation: University of Iowa, Department of Chemistry Education: BS (Caltech), PhD (Harvard), Postdoctoral Research Associate (Stanford) Research Focus Bowden’s group develops synthetic solutions for global challenges: organic solvent nanofiltration membranes to revolutionize chemical separation, growth promoters to enhance crop yields for food security, and hydrogen sulfide-releasing compounds for medical applications targeting cancer and ocular diseases. The group emphasizes commercialization , having launched two start-ups. Article Trends His publications span membrane technology (12/15), agricultural chemistry (4/15), and biomedical engineering (5/15), with recurring themes of cross-linked polymers , thiol-based chemistry , and controlled release mechanisms . Recent work (2020–2024) prioritizes epoxy membranes and H2S delivery systems . Grants and Collaborations In 2023, his team secured an NSF grant for membrane purification of fatty acids. Collaborations extend to pharmacy, biomedical engineering, neurosurgery, and agricultural science , reflecting his interdisciplinary approach. Advising and Lab Dynamics Bowden has mentored PhD students Nimesh and Arjun , who defended their theses in 2023, and continues guiding Jett and Vamsi (joined 2024). The lab integrates synthetic chemistry with practical implementation across industries.

Sandrine Cammas-Marionمشاهده پروفایل

پژوهشگر

• Polymer Chemistry
• Nanomedicine
• Drug Delivery Systems
• +۷ مورد دیگر

Sandrine Cammas-Marion is a CNRS Researcher affiliated with the Institute of Chemical Sciences of Rennes (ISCR, UMR 6226 CNRS) at the National School of Chemistry of Rennes (ENSCR) and the NuMeCan Institute (U-1241 Inserm - INRA - University of Rennes 1). She has held a continuous research position with CNRS since 1995, currently splitting her time equally between ISCR and NuMeCan, focusing on the development of degradable and biocompatible nano-platforms for therapy and diagnosis. Her work bridges polymer chemistry and biomedical applications, particularly in targeted drug delivery for hepatocellular carcinoma. Her research interests include the synthesis of degradable polyesters via anionic ring-opening polymerization, design of functionalized (co)polyesters carrying targeting agents or drugs, self-assembly of amphiphilic copolymers, and the development of multifunctional nanoparticles for targeted delivery. She has made significant contributions to poly(malic acid)-based systems and stimuli-responsive nanocarriers. The recent publications highlight a strong trend toward advanced drug delivery systems, particularly using poly(malic acid) and related copolymers. Research themes include targeted delivery (via RGD or galactosamine), NIR-responsive theranostics, biocompatibility studies, and enzyme-catalyzed polymerization. Her work integrates chemical synthesis, nanoparticle formulation, in vitro and in vivo evaluation, and translational nanomedicine. Scientific expertise and recognition are evident through her extensive peer-review activities for high-impact journals and evaluation of research projects for ANR, LabEx, and regional funding bodies. She has also contributed to scientific governance through roles in doctoral schools, scientific councils, and health and safety committees. She has co-authored numerous publications and book chapters on drug delivery, polymer design, and archaeal lipids. Her work often involves collaboration with experts in pharmacology, oncology, and materials science. She has contributed to major conferences and training initiatives in high-throughput experimentation and polymer science. Laboratory and team affiliations include the ISCR at ENSCR and the NuMeCan Institute, where she collaborates on interdisciplinary projects involving drug delivery, cancer therapy, and biomaterials. Her research is embedded in a strong network of national and international scientific collaborations.

• Molecular Medicine
• Pharmacology
• Oncology
• +۳ مورد دیگر

Roman Perez Fernandez is a Professor at the Department of Physiology, University of Santiago de Compostela. He is affiliated with the Faculty of Medicine and Dentistry, and leads research at the Center for Research in Molecular Medicine and Chronic Diseases (CIMUS) and the Strategic Grouping in Materials (AEMAT). His work focuses on designing bioactive compounds and materials , particularly vitamin D analogues and stem cell therapies. He holds a PhD from the University of Santiago de Compostela (1987) with a thesis on adrenal androgen physiology. Research interests include molecular mechanisms of cancer progression, anti-fibrotic therapies, and stem cell secretome applications. Notable areas include breast cancer metastasis regulation via POU1F1 transcription factor, and development of novel vitamin D-based drugs targeting oncologic and metabolic conditions. His studies also explore the therapeutic potential of human uterine cervical stem cells in regenerative medicine and anti-inflammatory treatments. Publications highlight advancements in: 1) Design of anti-cancer vitamin D analogs with reduced calcemic side effects; 2) Role of p63 in hepatic glucose metabolism and fibrosis; 3) Mechanisms of cancer stem cell reprogramming; 4) Anti-inflammatory effects of conditioned stem cell media in ocular and gastrointestinal disorders. His work bridges organic chemistry, molecular biology, and clinical applications. Awards and grants are not explicitly listed, but his extensive publication record (over 70 papers from 1987–2025) reflects sustained research excellence. He collaborates across disciplines including material science (AEMAT) and molecular medicine (CIMUS). Current projects involve optimizing drug delivery systems using hydrogels and cyclodextrin complexes for targeted therapies.

Rebecca Carrierمشاهده پروفایل

دانشیار

• Mucosal Drug Delivery
• Intestinal Barrier Function
• Bioengineering
• +۴ مورد دیگر

Rebecca Carrier is an Associate Professor of Chemical Engineering at Northeastern University, specializing in mucosal drug delivery and intestinal barrier function. Her work focuses on engineering biomimetic systems to study drug-mucus interactions, microbial dynamics, and gut physiology. She pioneered the development of gut-on-a-chip models to simulate human intestinal environments and has received a $1.8 million NIH grant to investigate lipid roles in drug absorption. Her research bridges chemical engineering, biomedical sciences, and pharmaceutical technologies. Education: Advanced degrees in chemical engineering and biomaterials science (details not specified). Labs/Teams: Leads Northeastern's gut microphysiological systems initiative, collaborating with pharmaceutical and biotechnology partners. Her research interests include optimizing drug delivery systems using mucus-mimetic materials and understanding how dietary lipids modulate gut barrier properties. She explores hydrogen sulfide's role in gut health and develops biosensors for anaerobic microenvironments. Carrier's organ-on-a-chip platforms enable study of Crohn's disease and microbial-host interactions, offering preclinical models for drug efficacy and toxicity testing. Recent studies highlight mucus's role in stabilizing drug supersaturation and its implications for oral formulations. She advocates for biorelevant in vitro models to predict drug behavior in physiological conditions. Carrier's interdisciplinary approach integrates microfluidics, polymer chemistry, and synthetic biology to address challenges in gastrointestinal health and drug delivery. Grant funding supports her work on lipid-enhanced drug absorption and mucosal barrier strengthening. She mentors graduate students in bioengineering and collaborates on projects like engineered bacteria for hydrogen sulfide regulation. Carrier's lab also develops decellularized extracellular matrix scaffolds for retinal regeneration studies, showcasing her broader impact in regenerative medicine.

Benjamin Boydمشاهده پروفایل

استاد پژوهشی

• Drug Delivery
• Pharmaceutical Sciences
• Nanotechnology
• +۳ مورد دیگر

Benjamin Boyd is a Research Professor at Monash University's Department of Drug Delivery Disposition & Dynamics. He holds teaching roles in the Bachelor of Pharmaceutical Sciences program, covering physical chemistry, drug development, and advanced formulation/nanotechnology. He coordinates the MIPS D4 HDR and Honours Programs. His research focuses on lipid-based drug delivery systems, colloidal formulations, and nanotechnology applications in medicine. Key research areas include lipid-based liquid crystalline systems, dendrimer drug carriers, and colloidal aspects of formulation design. His work contributes to UN Sustainable Development Goals related to health and innovation. Boyd has led/co-investigated over 74 projects since 2004, including recent initiatives like the Nano-Bioscience Imaging Facility (2025) and organosulfur surfactant research (2025-2028). He has published 350+ outputs, emphasizing drug delivery mechanisms and formulation optimization. Notable awards include the 2011 AAPS Award and 2018 Research Impact Award. Boyd holds patents related to drug delivery systems through collaborations with organizations like Starpharma Pty Ltd.

• Drug Delivery
• Nanoparticle Technology
• Vaccine Development
• +۳ مورد دیگر

Dr. Emily Pilkington is a Research Fellow in the Department of Drug Delivery, Disposition & Dynamics at Monash University. Her work focuses on advancing nanoparticle-based drug delivery systems and vaccine technologies, with a particular emphasis on lipid nanoparticles and their applications in mRNA vaccines and cancer immunotherapy. She leads a project titled Identifying and overcoming mechanisms of immune evasion in cancer , investigating strategies to enhance immune responses against tumors. Her research integrates materials science, immunology, and biomedical engineering to address challenges in targeted drug delivery and disease treatment. Dr. Pilkington has authored over 30 peer-reviewed publications, with notable contributions on nanoparticle design, PEG immunogenicity, and vaccine development. Her research interests span nanotechnology-driven solutions for infectious diseases, cancer therapy, and amyloidosis mitigation. Key projects include optimizing lipid nanoparticles for mRNA vaccines and exploring shape-controlled nanoparticles for targeted drug delivery. Collaborations with global teams highlight her interdisciplinary approach to solving complex biomedical challenges. Recent work highlights include breakthroughs in engineered ferritin nanoparticles for vaccine efficacy enhancement and studies on anti-PEG antibodies induced by mRNA vaccines. She is currently involved in an active research initiative (2025–2029) targeting cancer immune evasion mechanisms, positioning her at the forefront of translational biomedical research.

Huang Chiao Huangمشاهده پروفایل

استادیار

• Photodynamic therapy
• Precision cancer nanomedicine
• Mechanism-based combination therapy
• +۴ مورد دیگر

Huang Chiao Huang is an Assistant Professor in the Fischell Department of Bioengineering at the University of Maryland, College Park. His work integrates nanotechnology and photobiology to develop light-driven therapies for cancer and other diseases. He leads the Huang Lab , which focuses on engineering nanoscale systems for photodynamic therapy (PDT), drug delivery, and imaging. Research Interests: Photodynamic therapy and precision nanomedicine Mechanism-based combination therapies Site-directed photochemistry and fluorescence diagnostics Recent advances include light-activatable nanoparticles for tumor ablation and strategies to overcome multidrug resistance via photodynamic priming. His lab has secured major grants, including an NSF award for light-triggered ablation technology and two NIH R01 grants totaling $6M for brain tumor and peritoneal metastasis therapies. Grants & Funding: NSF Grant: Light-Triggered Ablation Technology (2025) NIH R01 Grants ($6M): Photothermal Therapy & Photodynamic Therapy (2023) MII Grant: Advanced Photodynamic Therapy for Tumors (2024) Lab & Education: The Huang Lab trains students in nanotechnology and photobiology, with initiatives to develop educational resources. Recent milestones include graduating 6 PhD students in 2025 and developing imaging tools like fluorescence laminar optical tomography for brain PDT monitoring.

• Polymer Synthesis
• Biomaterials
• Tissue Engineering
• +۷ مورد دیگر

Dr. Barbara Dittrich is a Project Leader specializing in polymer synthesis and biomaterials. She is actively involved in interdisciplinary research at the intersection of biotechnology, materials science, and biomedical engineering. Her work focuses on developing advanced polymer-based systems for applications in tissue engineering, drug delivery, and sustainable bioprocesses. Her research interests include polymer synthesis , biomaterials design , tissue engineering scaffolds , controlled release systems , and microalgal biotechnology . She has contributed to innovative projects such as smart polymers for virus detection (NARRATE), early overload indicators in protective gear (FrÜling), and sustainable flow chemistry (InFlow). The recent publications highlight a strong trend in functional biomaterials and bioprocess optimization . Her work spans from fundamental polymer chemistry to applied medical devices, demonstrating a translational research approach. Keywords across her articles reflect expertise in stem cells, antifouling surfaces, microreactors, and sustainable formulations. Dr. Dittrich leads multiple research projects, indicating active grant funding and team leadership. Although no scientific awards are listed, her consistent publication record in high-impact journals suggests recognition in her field. She collaborates with multidisciplinary teams across institutions, contributing to advancements in both academic and applied research settings. Her laboratory or research group appears to focus on polymer-based technologies for biomedical and environmental applications. Projects like SiO2 microcapsules for textiles and phosphate functionalization from renewable sources (ProPhos) suggest a strong emphasis on sustainability and real-world implementation.

Wei Gaoمشاهده پروفایل

استادیار

• Nanomedicine
• Cancer Immunotherapy
• Immunomodulation
• +۵ مورد دیگر

Wei Gao is an Assistant Professor of Pharmacology at the University of Houston College of Pharmacy, specializing in the Department of Pharmacological and Pharmaceutical Sciences. With a focus on nanomedicine and immunotherapy, Dr. Gao develops innovative strategies to modulate B cells and myeloid cells for treating cancer and immune diseases. B.S., School of Life Science and Technology, China Pharmaceutical University Master, School of Pharmacy, University of Calabria, Italy M.S. in Pharmaceutics, China Pharmaceutical University Ph.D. in Pharmaceutics, Peking University Health Science Center Postdoctoral Research Fellow (2017-2021) and Assistant Research Scientist (2022-2024), University of Michigan College of Pharmacy Dr. Gao’s research emphasizes nanovaccine development and overcoming STING pathway resistance in pancreatic cancer through regulatory B cell elimination. His work also explores albumin-based nanoformulations for lymphatic system targeting. Recent publications highlight advancements in tumor microenvironment-responsive nanoparticles, multidrug resistance reversal, and combinatorial immunotherapy strategies. Dr. Gao is a co-investigator on the NIH R01 CA285790-01 grant (2024-2029) and a member of the American Association for Cancer Research, Controlled Release Society, American Association of Pharmaceutical Scientists, and Society for Immunotherapy of Cancer.

Jung Soo Sukمشاهده پروفایل

دانشیار

• Biological Barriers
• Nanotechnology
• Therapeutic Delivery
• +۳ مورد دیگر

Jung Soo Suk, PhD , is an Associate Professor at the University of Maryland School of Medicine in the Department of Neurosurgery and holds adjunct appointments at the Johns Hopkins University School of Medicine in Neurosurgery and Chemical & Biomolecular Engineering. B.Eng., Chemical Engineering, Korea University (2001) M.S.E., Biomedical Engineering, Johns Hopkins University (2005) Ph.D., Biomedical Engineering, Johns Hopkins University School of Medicine (2011) Dr. Suk specializes in overcoming biological barriers (e.g., blood-brain barrier, airway mucus) through nanotechnology-based delivery systems , focusing on synthetic or natural materials (polymers, lipids, extracellular vesicles) for targeted therapies in cancers, genetic disorders, and lung diseases. His recent work expands into cancer immunotherapy , particularly mechanisms of immune resistance in malignancies. The 15 most recent articles highlight his expertise in nanoparticle design for drug delivery across biological barriers (e.g., brain, lungs, eyes), with a strong emphasis on preclinical validation and clinical translation . Trends include focused ultrasound for barrier opening, mRNA platforms for immunotherapy, and gene editing via advanced vectors. Scientific Awards : Korea University Merit-Based Scholarship (1998) Society of Experimental Biology & Medicine Best Paper Award (2007) Johns Hopkins Center for Nanomedicine Award for Research Excellence (2014) W.W. Smith Charitable Trust Research Award (2015) Acta Biomaterialia Reviewer Award (2018) Grants include funding from the National Institute of Health, Cystic Fibrosis Foundation, Focus Ultrasound Foundation, and TEDCO, covering projects like nanoparticle delivery for glioblastoma , inhaled gene therapy for COPD , and immunostimulatory antibody conjugates . Dr. Suk’s research team integrates material science , biophysics , and medical biology to develop safe, efficient therapeutic platforms for debilitating diseases.

Karen Wawrousekمشاهده پروفایل

دانشیار

• Synthetic biology and metabolic engineering of non-model bacteria
• Biofuels and biochemicals production from waste feedstocks
• Microbial ecology of extreme environments
• +۳ مورد دیگر

Karen Wawrousek is an Associate Professor in the Department of Chemical and Biomedical Engineering at the University of Wyoming, where she also serves as the ABET Coordinator. She is affiliated with the university’s College of Engineering and Applied Science and the interdisciplinary Molecular and Cellular Life Science Program . Her work integrates chemical engineering, microbiology, and bio-analytical chemistry to tackle global challenges in sustainable energy and public health. Education & Professional Experience Ph.D., Biochemistry & Molecular Biophysics, California Institute of Technology (2001–2009) Postdoctoral Scientist (Photobiology), National Renewable Energy Laboratory (2010–2011) Lead Scientist (Waste & Environmental Management), Western Research Institute (2012–2014) Research Interests Wawrousek’s group engineers non-model bacteria to convert low-value waste streams into high-value fuels and chemicals. Using organisms such as Rhodococcus opacus and Rubrivivax gelatinosus , her team has advanced metabolic pathways for biodiesel precursors, hydrogen, and commodity chemicals. Parallel projects explore microbial life in the deep subsurface, elucidating how extreme pressure, salinity, and nutrient limitation shape community structure and function. More recently, her laboratory pivoted to biomedical diagnostics, developing ultrasensitive SERS-based assays that detect SARS-CoV-2 in saliva at femtogram levels—work that emerged from an earlier initiative on novel point-of-care diagnostics. Publication & Patent Highlights Across 2022–2025, Wawrousek’s publications reveal a clear trajectory from fundamental microbial physiology toward applied bio-products and rapid diagnostics. Key themes include valorization of agricultural by-products (e.g., sugar beet molasses), nanomaterial-enhanced remediation, and plasmonic biosensors for viral antigens. Her patent portfolio (five granted or pending since 2017) protects innovations in CO₂-to-fuel bioprocessing, rare-earth recovery, and COVID-19 detection platforms. Current Funding & Collaborative Teams National Science Foundation – metabolic engineering of non-model bacteria for fuels and chemicals U.S. Department of Energy – microbial ecology of extreme subsurface environments Interdisciplinary COVID-19 diagnostics consortium involving virologists, immunologists, and optical engineers Laboratory & Infrastructure Research is conducted in Engineering Hall 4029, equipped for anaerobic microbiology, metabolic flux analysis, optical biosensor prototyping, and high-throughput SERS screening. The lab hosts graduate students and postdoctoral researchers drawn from chemical engineering, molecular biology, and environmental science programs at Wyoming’s R1 university.

Chandrabali Bhattacharyaمشاهده پروفایل

استادیار

• Organic Chemistry
• Glycochemistry
• Glycobiology
• +۵ مورد دیگر

Chandrabali Bhattacharya serves as Assistant Professor in the Department of Chemistry and Biochemistry at the University of Nevada, Las Vegas, where she founded and directs the mRNA Nanomedicine Program to advance mRNA therapeutics research in Nevada. Her work pioneers targeted delivery systems for mRNA using carbohydrate-protein interaction principles. Dr. Bhattacharya earned bachelor's and master's degrees in chemistry from Presidency College Kolkata and Indian Institute of Technology Kharagpur. She completed her Ph.D. in bioorganic chemistry at Arizona State University under Dr. Sidney M. Hecht, investigating bleomycin's disaccharide moiety in tumor targeting. Subsequent postdoctoral training included glycosaminoglycan research with Dr. Linda Hsieh-Wilson at Caltech and mRNA delivery development with Drs. Daniel Anderson and Robert Langer at MIT's Koch Institute as a Juvenile Diabetes Research Foundation Fellow. Her research integrates organic chemistry, glycobiology, and nanomedicine to design precision mRNA delivery vehicles. The Bhattacharya Lab specializes in glycolipid-based nanoparticles that target immune cells for cancer immunotherapy, including CAR-T cell engineering and personalized neoantigen vaccines. By leveraging disease-specific glycation patterns, her team develops 'living drugs' through reprogrammed T cells and dendritic cell-targeted vaccines. Analysis of her 2024-2025 publications reveals groundbreaking work in expanding mRNA delivery beyond liver/lung targets. Key innovations include Cortico LNPs for spleen-selective delivery (enabling autoimmune disease treatments) and ENDO LNPs for pancreatic targeting (with implications for diabetes and pancreatic cancer therapies). Her research consistently bridges fundamental glycochemistry with clinical translation in oncology and immunology. Her scientific recognition includes: Juvenile Diabetes Research Foundation Fellowship Supported by competitive research funding, Dr. Bhattacharya leads a multidisciplinary team developing next-generation delivery platforms. Her mRNA Nanomedicine Program fosters statewide collaboration to position Nevada as a hub for RNA therapeutics innovation, with current projects focused on overcoming tissue-specific delivery barriers for cancer and metabolic diseases. The Bhattacharya Lab operates at the chemistry-biology-engineering interface, combining synthetic organic chemistry with cellular immunology to solve delivery challenges. Future work will expand organ-targeting capabilities and accelerate clinical translation of mRNA-based cancer immunotherapies through industry partnerships and novel biomaterial design.